Trk Receptors

Zurletrectinib is a potent tyrosine kinase inhibitor that selectively targets TRK kinases (TRKA IC50 = 0.81 nM; TRKB IC50 = 0.145 nM; TRKC IC50 = 0.184 nM). Its enhanced binding affinity results in superior efficacy, especially against various resistance mutations (effectively targeting 13 out of 18 known mutations). This compound is particularly useful for research applications related to glioma and exploring TRK signaling pathways in tumor biology.

Tepotinib hydrochloride is a highly selective, reversible, ATP-competitive inhibitor of c-Met, exhibiting an IC50 of 3 nM and over 200-fold selectivity for c-Met compared to other kinases such as IRAK4, TrkA, Axl, IRAK1, and Mer. This compound effectively inhibits c-Met phosphorylation and promotes autophagy. Tepotinib hydrochloride demonstrates significant antitumor activity and is applicable in cancer research targeting c-Met-driven pathways.

Entrectinib-d8 is a deuterated derivative of Entrectinib, targeting TrkA/B/C, ROS1, and ALK receptors. This compound exhibits potent inhibitory effects with IC50 values of 1 nM for TrkA, 3 nM for TrkB, 5 nM for TrkC, and 12 nM for ROS1 and ALK. Entrectinib-d8 is effective in inducing apoptosis and cell cycle arrest in various cancer cell lines, demonstrating significant anti-tumor activity. Additionally, it has been shown to alleviate bleomycin-induced pulmonary fibrosis in murine models, making it a valuable tool for research in cancer and fibrosis therapies.

PF-07245303 is an ITK/TRK inhibitor that effectively reduces the production of pro-inflammatory cytokines such as IL-4 and IFNγ. This compound inhibits the phosphorylation of PLCγ1 and disrupts nerve growth factor-induced basophil activation and TRKA phosphorylation. Additionally, PF-07245303 demonstrates a reduction in oxazolone-induced ear swelling in mouse models, making it a valuable tool for research into atopic dermatitis and related inflammatory conditions.